Trial
NCT06843187
Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Unity Health Toronto
Collaborators
University of Toronto; Centre for Addiction and Mental Health; Toronto Metropolitan University
Condition
Major Depressive Disorder(MDD)
Intervention
Lemborexant
Why stopped
Funding withdrawn by sponsor.
Provenance
Dataset: 2026-07-31 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-30